PRTO Proteon Therapeutics, Inc.

1.50
0  -6%
Previous Close 1.60
Open 1.60
Price To book 0.69
Market Cap 24.90M
Shares 16,603,000
Volume 85,157
Short Ratio 2.06
Av. Daily Volume 83,819

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 enrollment to be completed 4Q 2017. Data due 4Q 2018.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)